Dual inhibition of neutral endopeptidase and angiotensin-converting enzyme in rats with hypertension and diabetes mellitus

Hypertension

Volumn 32, Issue 4, 1998, Pages 778-785

  Tikkanen, Tuula ^a,b   Tikkanen, Ilkka ^a,b,c   Rockell, Melinda D ^a   Allen, Terri J ^a   Johnston, Colin I ^a   Cooper, Mark E ^a   Burrell, Louise M ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b MINERVA FOUNDATION INSTITUTE FOR MEDICAL RESEARCH   (Finland)

^c UNIVERSITY OF HELSINKI   (Finland)

Author keywords

Albuminuria; Angiotensin; Blood pressure; Natriuretic peptides; Renal circulation

Indexed keywords

CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENKEPHALINASE INHIBITOR; MEMBRANE METALLOENDOPEPTIDASE; N (2 MERCAPTOMETHYL 3 PHENYLBUTYRYL)ALANINE; N [2 (ACETYLTHIOMETHYL) 3 (2 METHYLPHENYL)PROPIONYL]METHIONINE ETHYL ESTER; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AUTORADIOGRAPHY; CONTROLLED STUDY; DIABETES MELLITUS; DRUG EFFECT; DRUG SCREENING; ENZYME INHIBITION; HYPERTENSION; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEINURIA; RAT; SPONTANEOUSLY HYPERTENSIVE RAT; STREPTOZOCIN DIABETES;

EID: 0031785220     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.HYP.32.4.778     Document Type: Article

References (39)

1. Gansevoort RT, Sluiter WJ, Hemmelder MH, de Zeeuw D, de long PE. Antiproteinuric effects of blood-pressure lowering agents: a meta-analysis of comparative trials. Nephrol Dial Transplant. 1995;10:1963-1974.
2. Feldt-Rasmussen B, Mathiesen ER, Deckert T. Central role of sodium in the pathogenesis of blood pressure changes independent of angiotensin, aldosterone and catecholamines in type 1 (insulin-dependent) diabetes mellitus. Diabetologia. 1987;30:610-617.
3. Strojek K, Grzeszczak W, Lacka B, Gorska J, Keller CK, Ritz E. Increased prevalence of salt sensitivity of blood pressure in IDDM with and without albuminuria. Diabelologia. 1995;38:1443-1448.
4. Tikkanen I, Johnston CI. Comparison of renin-angiotensin to calcium channel blockade in renal disease. Kidney Int. 1997;52(suppl 63): S-19-S-22.
5. Johnston CI, Risvanis J, Naitoh M, Tikkanen I. Mechanisms of progression of renal disease: current haemodynamic concepts. J Hypertens. 1998. In press.
6. Roques BP, Noble F, Dauge V, Fournie-Zaluski M-C, Beaumont A. Neutral endopeptidase 24.11: structure, inhibition, and experimental and clinical pharmacology. Pharmacol Rev. 1993;45:87-146.
7. Erdös EG, Skidgel RA. Neutral endopeptidase 24.11 (enkephalinase) and related regulators of peptide hormones. FASEB J. 1989;3:145-151.
8. Abassi ZA, Tate JE, Golomb E, Keiser HR. Role of neutral endopeptidase in the metabolism of endothelin. Hypertension. 1992;20:89-95.
9. Sybertz EJ. Drugs inhibiting the metabolism and inactivation of atrial natriuretic factor: pharmacological actions and therapeutic implications. Cardiovasc Drug Rev. 1990;8:71-82.
10. Richards MA, Wittert GA, Grozier IG, Espiner EA, Yandle TG, Ikram H, Frampton C. Chronic inhibition of endopeptidase 24.11 in essential hypertension: evidence for enhanced atrial natriuretic peptide and angiotensin II. J Hypertens. 1993;11:407-416.
11. Wilkins MR, Unwin RJ, Kenny AJ. Endopeptidase-24.11 and its inhibitors: potential therapeutic agents for edematous disorders and hypertension. Kidney Int. 1993;43:273-285.
12. Sybertz EJ, Chiu PJS, Vemulapalli S, Pitts B, Foster CJ, Wtkins RW, Barnett A, Haslanger MF. SCH 39370, a neutral metalloendopeptidase inhibitor, potentiates biological responses to atrial natriuretic factor and lowers blood pressure in desoxycorticosterone acetate-sodium hypertensive rats. J Pharmacol Exp Ther. 1989;250:624-631.
13. Pham I, Gonzales W. El Amrani A-IK, Fournié-Zaluski M-C, Philippe M, Laboulandine I, Roques BP, Michel J-B. Effects of converting enzyme inhibitor and neutral endopeptidase inhibitor on blood pressure and renal function in experimental hypertension. J Pharmacol Exp Ther. 1993;265: 1339-1347.
14. Johnston CI, Naitoh M, Risvanis J, Farina N, Burrell LM. New hormonal blockade strategies in cardiovascular disease. Scand Cardiovasc J. 1998; 47(suppl):61-66.
15. Fournié-Zaluski MC, Gonzalez W, Turcaud S, Pham I, Roques BP, Michel JB. Dual inhibition of angiotensin-converting enzyme and neutral endopeptidase by the orally active inhibitor mixanpril: a potential therapeutic approach in hypertension. Proc Natl Acad Sci U S A. 1994;91: 4072-4076.
16. French JF, Anderson BA, Downs TR, Dage RC. Dual inhibition of angiotensin-converting enzyme and neutral endopeptidase in rats with hypertension. J Cardiovasc Pharmacol. 1995;26:107-113.
17. Seymour AA, Asaad MM, Abboa-Offei BE, Smith PL, Rogers WL, Dorso CR. In vivo pharmacology of dual neutral endopeptidase/angiotensin-converting enzyme inhibitors. J Cardiovasc Pharmacol. 1996;28: 672-678.
18. Gonzalez W, Fournié-Zaluski M-C, Turcaud S, Roques B-P, Michel J-B. Pharmacology of S21402 (RB105): a dual inhibitor of neutral endopeptidase, angiotensin-converting enzyme. Cardiovasc Drugs Rev. 1996;14: 166-184.
19. Zhang PL, Mackenzie HS, Tray JL, Brenner BM. Effects of an atrial natriuretic peptide receptor antagonist on glomerular hyperfiltration in diabetic rats. J Am Soc Nephrol. 1994;4:1564-1570.
20. Ortola F, Ballermann BJ, Anderson S, Mendez RE, Brenner BM. Elevated plasma atrial natriuretic peptide levels in diabetic rats, potential mediator of hyperfiltration. J Clin Invest. 1987;80:670-674.
21. Sakamoto K, Kikkawa R, Haneda M, Shigeta Y. Prevention of glomerular hyperfiltration in rats with streptozotocin-induced diabetes by an atrial natriuretic peptide receptor antagonist. Diabetologia. 1995;38:536-542.
22. 125I]RB104, a potent inhibitor of neutral endopeptidase 24.11, and its use in detecting nanogram quantities of the enzyme by "inhibitor gel electrophoresis." Proc Natl Acad Sci U S A. 1992;89:6388-6392.
23. Bunag RD. Validation in awake rats of a tail-cuff method for measuring systolic pressure. J Appl Physiol. 1973;34:279-282.
24. Allen TJ, Cooper ME, O'Brien RC, Bach LA, Jackson B, Jerums G. Glomerular filtration rate in the streptozotocin diabetic rat: the role of exchangeable sodium, vasoactive hormones and insulin therapy. Diabetes. 1990;38:1182-1190.
25. Cooper ME, Rumble JR, Allen TJ, O'Brien RC, Jerums G, Doyle AE. Antihypertensive therapy in a model combining spontaneous hypertension with diabetes. Kidney Int. 1992;41:898-903.
26. Johnston CI, Mendelsohn F, Casley DJ. Evaluation of renin and angiotensin assays and their clinical applications. Med J Aust. 1971;1:126-128.
27. Burrell LM, Palmer J, Charlton JA, Thomas T, Baylis PH. A new radioimmunoassay for human alpha atrial natriuretic peptide and its physiological validation. J Immunoassay. 1990;11:159-175.
28. Ogawa K, Smith AI, Hodsman GP, Jackson B, Woodcock EA, Johnston CI. Plasma atrial natriuretic peptide: concentrations and circulating forms in normal man and patients with chronic renal failure. Clin Exp Pharmacol Physiol. 1987;14:95-102.
29. Schmidt FH. Enzymatic determination of glucose and fructose simultaneously. Klin Wochenschr. 1961;39:1244-1247.
30. Cefaiu WT, Wang ZQ, Bell Farrow A, Kiger FD, Izlar C. Glycohemoglobin measured by automated affinity HPLC correlates with both short-term and long-term antecedent glycemia. Clin Chem. 1994;40:1317-1321.
31. Cooper ME, Allen TJ, O'Brien RC, Macmillan PA, Clarce B, Jerums G, Doyle AE. Effects of genetic hypertension on diabetic nephropathy in the rat: functional and structural characteristics. J Hypertens. 1988; 6:1009-1016.
32. Burrell LM, Farina NK, Risvanis J, Woollard D, Casley D, Johnston CI. Inhibition of neutral endopeptidase, the degradative enzyme for natriuretic peptides, in rat kidney after oral SCH 42495. Clin Sci. 1997;93:43-50.
33. Snedecor GW, Cochran WG. Statistical Methods. 7th ed. Ames, Iowa: Iowa State University Press; 1980:228-236.
34. Gonzales VW, Fournié-Zaluski M-C, Pham I, Laboulandine I, Roques B-P, Michel J-B. Hypotensive and natriuretic effects of RB 105, a new dual inhibitor of angiotensin converting enzyme and neutral endopeptidase in hypertensive rats. J Pharmacol Exp Ther. 1995;272:343-351.
35. Farina NK, Burrell LM, Teo LO, Johnston CI. Regression of cardiac hypertrophy by neutral endopeptidase and angiotensin converting enzyme inhibition in hypertensive rats. J Hypertens. 1996;14(suppl 1):S97. Abstract.
36. Ruskoaho H. Atrial natriuretic peptide: synthesis, release and metabolism. Pharmacol Rev. 1992;44:479-602.
37. Cooper ME, Allen TJ, Macmillan P, Bach L, Jerums G, Doyle AE. Genetic hypertension accelerates nephropathy in the streptozotocin diabetic rat. Am J Hypertens. 1988;1:5-10.
38. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD, for the Collaborative Study Group. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med. 1993;329:1456-1462.
39. Fabris B, Jackson B, Johnston CI. Salt blocks the renal benefits of ramipril in diabetic hypertensive rats. Hypertension. 1991;17:497-503.